CDTX(Delisted)
Cidara Therapeutics·NASDAQ
--
--(--)
6.47 / 10
Outperform
Capital flow assessment yields 7.49/10, denoting robust fund flow characteristics. Strengths in overall, block, Small, and Extra-large trends confront pressures from Medium and Large patterns, resulting in positive liquidity outlook. Analyst sentiment reflects cautiously optimistic analyst perspective with balanced view. The rating profile includes Strong Buy(20.0%), Buy(20.0%), Neutral(60.0%) from 5 analytical reports, supported by 5.46 historical weighted rating.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
20%
Buy
20%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-11-07
InstitutionRBC Capital
Times predicted2
Historical Win Rate100.0%
Is money flowing into or out of CDTX?
- CDTX holds a Bullish analyst rating, with 20% of experts assigning a Strong Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 6.47/10 (Outperform).
